Post-Approval & Lifecycle Management
Approval is the beginning of a product's regulatory life, not the end. We manage the ongoing regulatory operations that keep products on the market, compliant, and commercially viable: variations, renewals, labelling updates, line extensions, new indications, product transfers, safety-driven changes, and market expansions. We write the dossiers, submit the applications, and handle the authority interactions across regions. For companies that need MAH infrastructure, legal representation, or named compliance roles (EEA/EU QPPV, Stufenplanbeauftragter, Drug Information Officer), we provide those too.
Examples of How We Support
Below are examples to illustrate the kind of post-approval work we do day to day. The fastest way to find out more is usually via a short call; this will help us to understand your specific challenges and to explore how we can help.
Regulatory maintenance overload
You have marketed products across multiple EU member states and the regulatory maintenance is overwhelming your internal team. Variations are piling up, renewal deadlines are approaching, labelling updates need coordination across languages and markets, and nobody has time to track it all. You need someone to take over the operational load.
Post-approval variations
You need to implement a post-approval change (manufacturing site transfer, new supplier, process change, specification update) and aren't sure how to classify it under the revised EU Variations framework that took effect on 15 January 2026. You need someone who knows the new classification guideline and can prepare and submit the variation correctly.
Line extensions and switches
You're planning a line extension or new indication for an existing product and need the regulatory strategy, the dossier updates, and the submission management. This could be a new strength, a new dosage form, a paediatric formulation, or an Rx-to-OTC switch.
MAH transfer
You've acquired or in-licensed a product and need to transfer the marketing authorisation, update the dossier to reflect the new MAH, and set up the post-approval infrastructure (PV system, quality system, local representation) from scratch or transition it from the previous holder.
Outsourced compliance roles
You need MAH infrastructure and named compliance roles but don't want to build them in-house. You need an EEA/EU QPPV, local QPPVs, a Stufenplanbeauftragter (German drug safety officer), a Drug Information Officer, an EU Authorised Representative for devices, or a Responsible Person for wholesale distribution. You want these functions operational immediately, not after a 6-month recruitment process.
Understanding Post-Approval & Lifecycle Management
Post-approval work covers everything that happens to a product's regulatory dossier after the initial marketing authorisation or CE marking. For pharmaceuticals, this means variations (Type IA, IB, II), renewals, line extensions, PSUR-driven labelling changes, Rx-to-OTC switches, product transfers, and sunset clause management. For medical devices, it means technical documentation updates, Notified Body re-certification, design changes, PMS-driven modifications, and FSCA/field safety actions.
This page covers the regulatory operations side of post-approval work. For safety reporting and signal management, see Pharmacovigilance & Device Vigilance. For the CMC content behind a manufacturing change, see Pharmaceutical Development & CMC. For quality system maintenance and inspection support, see Quality & Compliance.
What We Do
Our Workstreams
Post-approval work is structured around these operational domains. Most marketed products require activity across several of them simultaneously.
Variations management
Classification under the revised EU framework (from 15 January 2026). Preparation and submission of Type IA (individual and annual updates), IB, II variations, and extensions. Grouping and worksharing strategies for multi-product or multi-market changes. PACMP planning per EMA's December 2025 revised guidance. Co-ordination of submissions in other markets including UK submission via International Recognition Procedure (IRP) after EU approval.
Renewals & maintenance
Five-year MA renewals, including benefit-risk bridging reports and addendum dossiers. Sunset clause monitoring and management. Annual IA update compilation. Product information maintenance (SmPC, PIL, labelling) across languages and markets.
Line extensions & new indications
Regulatory strategy for new strengths, dosage forms, routes of administration, paediatric extensions (PIP compliance), and Rx-to-OTC switches. Dossier preparation and submission management. Scientific advice preparation for new indication programmes.
Product transfers & restructuring
MA transfer variations (administrative and procedural). PV system and QMS transition planning. Notification to national competent authorities. Dossier updates to reflect new MAH, manufacturing sites, or supply chain changes.
MAH infrastructure & legal roles
Outsourced EEA/EU QPPV and local QPPV network. Stufenplanbeauftragter (German drug safety officer). Drug Information Officer (DIO). EU Authorised Representative for medical devices under MDR. Responsible Person (RP) for wholesale distribution. All roles operated under Regenold's own licences and compliance systems.
Device lifecycle management
Technical documentation updates post-CE marking: design changes, material changes, supplier changes, labelling updates, and integration of post-market surveillance findings. Design change assessments against MDR Annex II requirements. Notified Body re-certification submissions and audit support. EUDAMED and UDI database maintenance. PMS and PMCF-driven modifications to clinical evaluation, risk management, and technical documentation. Field safety corrective actions (FSCA): documentation, authority notification via manufacturer incident reports, and field safety notice preparation. IVDR transition activities for legacy IVDs, including classification under the new risk framework and performance evaluation updates.
Where This Fits in the Development Journey
Post-approval work is concentrated in the later phases but good lifecycle planning starts earlier.
Regulatory Submission & Approval
Plan the post-approval variation strategy alongside the initial submission. Identify post-approval commitments and establish the timeline for meeting them. Set up MAH infrastructure and compliance roles before the MA is granted.
Launch & Market Access
Execute the first wave of post-approval activities: labelling finalisation, local market registrations via regulanet®, PV system activation, and MAH operational readiness. Coordinate packaging and supply chain documentation.
Post-Market & Lifecycle Management
Ongoing variation management, renewals, line extensions, product transfers, labelling updates, PSUR-triggered changes, device technical documentation updates, NB re-certifications, and global dossier maintenance.
Sample Deliverables
These are typical outputs from our post-approval and lifecycle management engagements:
Variation dossier (Type IA, IB, or II) prepared and submitted under the revised EU Variations framework, including classification justification, supporting documentation, and eCTD compilation. 
Grouped variation package for multi-product manufacturing site transfer, coordinated across MRP/DCP member states. 
MA renewal dossier with benefit-risk bridging report, compliance summary, and updated Module 1 documentation. 
Line extension regulatory strategy and submission package (new strength or dosage form), including updated Modules 1, 2, and 3. 
MA transfer variation package with QMS and PV transition plan, submitted to all relevant national competent authorities. 
Labelling update coordination package: updated SmPC, PIL, and outer packaging texts across all authorised languages and markets, with cross-reference to the triggering variation or safety update. 
Post-Approval Change Management Protocol (PACMP) per the revised EMA guidance (December 2025), submitted as part of a Type II variation. 
Outsourced EEA/EU QPPV service agreement with ongoing PV system maintenance, signal management support, and periodic reporting. Example Projects
Illustrative Example
Generic pharma company: full lifecycle management outsourcing for a 30-product portfolio
A generics company with products authorised across 15 EU member states needed to outsource all post-approval regulatory operations. We took over variation management, renewal tracking, labelling coordination, and authority correspondence for the full portfolio. Within the first year, we cleared a backlog of 40+ overdue variations, completed 5 renewals, and established a rolling lifecycle plan for all products.
Illustrative Example
Mid-size pharma: MA transfer and infrastructure setup after product acquisition
A company acquired a marketed product but had no EU MAH infrastructure. We managed the MA transfer variation across 8 member states, set up the PV system (including EU QPPV and Stufenplanbeauftragter appointments), transitioned the quality system, and coordinated with the previous MAH to ensure no gap in regulatory compliance. The transfer was completed within 5 months with no supply interruption.
Illustrative Example
Medical device manufacturer: technical documentation update and NB re-certification after design change
A device manufacturer made a material change to an implantable device and needed to update the technical documentation and obtain Notified Body re-certification under MDR. We assessed the change, updated the risk management file, revised the biocompatibility evaluation, compiled the technical documentation update package, and managed the NB submission. Re-certification was granted without additional information requests.
Product Type Considerations
Lifecycle management requirements differ substantially by product type. The variation frameworks, renewal mechanisms, and regulatory maintenance obligations vary.
Small molecules
High variation volume driven by manufacturing changes, supplier updates, and specification revisions. Rx-to-OTC switches and generic competition create additional lifecycle pressure. The revised EU Variations framework (from 15 January 2026) reclassifies some previously Type II changes to Type IB, which may streamline certain CMC updates.
Medical devices
Technical documentation updates triggered by design changes, material changes, or PMS findings. Notified Body re-certification under MDR. IVDR transition for legacy IVDs still ongoing. FSCA documentation and authority notification for field safety issues.
Biologics & ATMPs
Comparability-driven variations for manufacturing changes. Complex variation classification for process modifications. Post-approval commitments from conditional MAs or PRIME-supported approvals often require coordinated follow-up submissions.
Combination products
Dual lifecycle: pharma variations for the drug component and device documentation updates for the device component. Changes to the device may trigger both a variation and a Notified Body re-assessment under Article 117.
Products in multiple markets
Global variation coordination: one change, multiple dossier updates across regions with different requirements and timelines. regulanet® coordination for markets outside Regenold's direct footprint. Dossier consistency management across 90+ countries.
Managing a marketed product portfolio, planning a line extension, or setting up post-approval infrastructure?
Tell us about your products and what you need, and we'll outline how we can help.
Contact usFrequently Asked Questions (FAQ)
What changed with the EU Variations framework on 15 January 2026?
The revised Variations Guidelines and updated Classification Guideline replaced the 2013 framework. Key changes include reclassification of some Type II variations to Type IB (for example, design space changes), updated documentation expectations for each category, clearer guidance on grouping and worksharing, formal integration of PACMPs, and an updated electronic application form. The underlying Variation Regulation (EU) 2024/1701 has been applicable since 1 January 2025, but the new Classification Guideline only applies to variations submitted from 15 January 2026.
How do you handle variations across multiple EU member states?
For products authorised via MRP or DCP, we coordinate the variation submission with the Reference Member State and all Concerned Member States simultaneously. For grouped or workshared variations affecting multiple products, we design the grouping strategy to minimise the number of separate submissions while meeting each authority's requirements. For markets outside the EU, we coordinate through regulanet® to align timing and documentation.
What is a PACMP and when should I use one?
A Post-Approval Change Management Protocol is a regulatory tool that lets you pre-agree with authorities on the data requirements and variation type for a planned future change. Once the PACMP is approved (typically via a Type II variation), implementing the change later can be submitted as a lower-risk variation (Type IA, IAIN, or IB). EMA revised the PACMP guidance in December 2025. PACMPs are most useful for planned manufacturing changes where you want predictability, such as site transfers or scale-up.
Can you manage lifecycle activities for products we've acquired or in-licensed?
Yes. We handle the full MA transfer process: the administrative variation, dossier updates, PV system transition, QMS handover, and coordination with national authorities. We also set up the post-transfer compliance infrastructure (EU QPPV, Stufenplanbeauftragter, DIO) and take over ongoing lifecycle management from the first day after transfer.
What does an outsourced EEA/EU QPPV arrangement look like?
We provide the named EEA/EU QPPV and (where needed) local QPPVs across EU member states. The QPPV operates within our pharmacovigilance system, with access to your safety database and reporting channels. We maintain the PV System Master File, manage signal detection and PSUR authoring (or coordinate with your existing PV provider), and handle authority interactions on safety matters. This is an ongoing service, not a one-off appointment.
Do you handle device lifecycle management as well as pharma?
Yes. For medical devices, we manage technical documentation updates after CE marking, design change assessments, Notified Body re-certification submissions under MDR, PMS-driven modifications, and FSCA documentation. For IVDs, we also support IVDR transition activities for legacy devices still moving to the new regulatory framework.
How do you coordinate lifecycle activities globally?
Through regulanet®, our network of independent regulatory service providers in 90+ countries. We develop the core variation or update package centrally and coordinate local adaptation, translation, and submission through network partners. You can sign one contract with us and get coordinated execution worldwide.
What is involved in a field safety corrective action (FSCA) for a medical device?
An FSCA is any corrective action taken by a manufacturer to reduce a risk of death or serious deterioration in health associated with a device already on the market. This can range from a device recall or modification to updated instructions for use or a software patch. We support the full process: risk assessment, decision on the appropriate corrective action, preparation of the manufacturer incident report for the competent authority, drafting of the field safety notice for users, coordination with the Notified Body, and documentation of the FSCA in the technical file and PMS records.